NEOS Investment Management LLC Raises Holdings in CVS Health Corporation $CVS

NEOS Investment Management LLC raised its position in CVS Health Corporation (NYSE:CVS) by 12.9% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 206,750 shares of the pharmacy operator’s stock after purchasing an additional 23,637 shares during the period. NEOS Investment Management LLC’s holdings in CVS Health were worth $21,388,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC lifted its stake in shares of CVS Health by 41.8% in the second quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock worth $37,000 after buying an additional 105 shares in the last quarter. Apella Capital LLC raised its holdings in CVS Health by 1.7% in the 2nd quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock valued at $724,000 after acquiring an additional 117 shares during the last quarter. CYBER HORNET ETFs LLC lifted its stake in CVS Health by 4.1% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after purchasing an additional 134 shares in the last quarter. Northwestern Mutual Investment Management Company LLC lifted its stake in CVS Health by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock worth $3,219,000 after purchasing an additional 136 shares in the last quarter. Finally, CoreCap Advisors LLC boosted its holdings in shares of CVS Health by 4.2% during the 2nd quarter. CoreCap Advisors LLC now owns 3,481 shares of the pharmacy operator’s stock worth $360,000 after purchasing an additional 139 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Down 0.4%

Shares of CVS opened at $96.80 on Friday. The company’s 50-day moving average price is $100.79 and its 200 day moving average price is $90.14. CVS Health Corporation has a 12-month low of $69.51 and a 12-month high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The firm has a market cap of $123.80 billion, a P/E ratio of 25.61, a price-to-earnings-growth ratio of 0.95 and a beta of 0.59.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts forecast that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.7%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is 70.37%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CVS shares. JPMorgan Chase & Co. increased their price target on CVS Health from $111.00 to $118.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Weiss Ratings upgraded CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Piper Sandler reissued an “overweight” rating on shares of CVS Health in a research report on Wednesday, August 26th. Royal Bank Of Canada lifted their target price on shares of CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research note on Thursday, July 9th. Finally, Robert W. Baird set a $107.00 price target on shares of CVS Health in a research note on Thursday, August 6th. Twenty-two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and an average price target of $106.83.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.